We caught up with Ronald van Vollenhoven (Amsterdam University Medical Centers, Amsterdam, the Netherlands) to discuss the use of ustekinumab in patients with active systemic lupus erythematosus (Clinical Trial Identifier: NCT02349061). The abstract ‘Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study’ (ABSTRACT NUMBER: 1826) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What is the rationale for the use of ustekinumab in the treatment of systemic lupus erythematosus (SLE)? (0:26)
- Could you tell us a little about the Phase 2 study you are presenting, and its findings? (1:31)
- What are the challenges in selecting clinical endpoints for SLE studies? (3:15)
- What were the strengths and limitations of this study? (4:28)
- How will these findings inform future research? (5:50)
Disclosures: Research Support (institutional grants): BMS, GSK, Lilly, UCB. Support for Educational programs (institutional grants): Pfizer, Roche. Consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB. Speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
